

PharmSci 2020

Open Science and Drug Discovery: Basic Research to New Medicines

Tuesday, March 3, 2020, 8:00 a.m. - 4:00 p.m.

The Rizzo Center, Chapel Hill, NC

Keynote	Open science, from gene to medicine Aled Edwards, CEO, SGC
Basic	Leveraging open lab notebooks for rare disease drug discovery Rachel Harding, U. Toronto, Canada Diversifying the AD target pipeline through open science Lara Mangravite, Sage Bionetworks, Seattle WA Open Targets: drug target identification and prioritisation in a pre-competitive partnership Ian Dunham, Sanger Institute, Cambridge UK Open science as a mission enabler in neurology Edward Fon, The Neuro, Montreal, Canada
Translation	Development of clinical inhibitors for the rare disease FOP and brain tumour DIPG Alex Bullock, Oxford UK Open sourcing drug discovery and how we might sustain it Mat Todd, University College London UK Deploying DEL technologies to enhance open science discovery Christelle Huguet, X-Chem, Waltham MA opnMe.com, a successful digital platform for openly sharing tools with the biomedical research community Adrian Carter, Boehringer Ingelheim, Germany
Value Creation Social and Economic	Increasing social and economic impact through open science Panelist Maryann Feldman, UNC Kenan-Flagler Business School Panelist Tetsuyuki Maruyama, former head of Takeda Research, Dementia Discovery Fund, Japan Panelist TBD